We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Harvard Bioengineers’ Biomaterial-Based Cancer Immunotherapies to be Developed by Novartis

News   Mar 23, 2018 | Original story from The Wyss Institute

 
Harvard Bioengineers’ Biomaterial-Based Cancer Immunotherapies to be Developed by Novartis

Made of the polymer that’s used in biodegradable sutures, this aspirin-sized device is designed to deliver immunotherapy agents that activate the immune system against tumors. Image courtesy of the Wyss Institute at Harvard University

 
 
 

RELATED ARTICLES

Vaccine Shows Promise Against Chicken Disease

News

A new vaccine strategy could offer protection to millions of chickens threatened by a serious respiratory disease.

READ MORE

Progress in Cochlear Regeneration

News

This research demonstrates a signaling pathway that can be activated by different methods and could represent a new approach to cochlear regeneration and, ultimately, restoration of hearing.

READ MORE

Drug Combo Destroys Chemo-resistant Blood Cancer

News

Researchers have developed a promising targeted strategy to treat chemotherapy-resistant acute myeloid leukemia (AML) and a diagnostic test to determine which AML patients would most likely benefit from this treatment.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE